Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

App aims to boost blood sugar control in type 1 diabetes

NCT ID NCT06819306

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a smartphone app called Hedia Diabetes Assistant can help adults with type 1 diabetes keep their blood sugar in a healthy range more often. About 154 people with poorly controlled diabetes will either use the app plus their usual care or just usual care for 6 months. The main goal is to see if the app increases the time blood sugar stays between 70 and 180 mg/dL.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 154 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Signed informed consent * Aged ≥ 18 years at the time of signing the informed consent * Ability to understand, speak and read French fluently * Diagnosed with type 1 diabetes \> 12 months prior to the day of screening TIR \<70% of last 14 days or HbA1c \>53 mmol/mol (7%) measured within the last month * Subject must have the cognitive and physical skills to use mobile applications * Access to a smartphone with iOS version 16 and up or Android version 12 and up * Treated with the same pen-based insulin regimen with basal insulin (insulin glargine, degludec, or detemir) and rapid-acting insulin (insulin aspart, lispro, glulisine) for at least the three preceding months * rtCGM use ≥ 1 month from screening date with ≥70% measurements for the last ≥ 14 days * Willing to use the same type of CGM for the duration of the clinical investigation * Willing to be telemonitored during the study period * If female participants of childbearing potential; willing to have a pregnancy test performed and to use a highly effective method of contraception * Affiliated to the French social security system Exclusion Criteria: * Use of human insulin or premixed insulin * Using a bolus calculator as a part of standard of care treatment at the time of screening * If the principal investigator deems that subjects are not healthy, not capable of completing the investigation or in other ways deemed unfit for participation in the investigation * Ongoing participation in other interventional clinical trials or investigations during the investigation period if the principal investigator deems this to potentially affect the safety, clinical performance and/or any study outcomes * Female who is pregnant, breast-feeding or intends to be pregnant during the investigation period * Participant under guardianship, conservatorship, safeguard of justice, or any other legal protection measure for a vulnerable adult

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes mellitus (T1DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire d'Angers

    Angers, France

  • Centre hospitalier universitaire de Nantes

    Nantes, France

  • Centre hospitalier universitaire de Nîmes

    Nîmes, France

  • Centre hospitalier universitaire de Poitiers

    Poitiers, France

  • Hospices Civils de Lyon

    Lyon, France

  • Hôpital Bichat - Claude-Bernard

    Paris, 75018, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.